These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 28625368)

  • 1. Effect of aspirin on renal disease progression in patients with type 2 diabetes: A multicenter, double-blind, placebo-controlled, randomized trial. The renaL disEase progression by aspirin in diabetic pAtients (LEDA) trial. Rationale and study design.
    Violi F; Targher G; Vestri A; Carnevale R; Averna M; Farcomeni A; Lenzi A; Angelico F; Cipollone F; Pastori D
    Am Heart J; 2017 Jul; 189():120-127. PubMed ID: 28625368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aspirin and renal insufficiency progression in patients with atrial fibrillation and chronic kidney disease.
    Pastori D; Pignatelli P; Perticone F; Sciacqua A; Carnevale R; Farcomeni A; Basili S; Corazza GR; Davì G; Lip GYH; Violi F;
    Int J Cardiol; 2016 Nov; 223():619-624. PubMed ID: 27565838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial.
    Heerspink HJ; Persson F; Brenner BM; Chaturvedi N; Brunel P; McMurray JJ; Desai AS; Solomon SD; Pfeffer MA; Parving HH; de Zeeuw D
    Lancet Diabetes Endocrinol; 2016 Apr; 4(4):309-17. PubMed ID: 26774608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aspirin for Primary Prevention of Cardiovascular Disease and Renal Disease Progression in Chronic Kidney Disease Patients: a Multicenter Randomized Clinical Trial (AASER Study).
    Goicoechea M; de Vinuesa SG; Quiroga B; Verde E; Bernis C; Morales E; Fernández-Juárez G; de Sequera P; Verdalles U; Delgado R; Torres A; Arroyo D; Abad S; Ortiz A; Luño J
    Cardiovasc Drugs Ther; 2018 Jun; 32(3):255-263. PubMed ID: 29943364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Vitamin D and Omega-3 Fatty Acid Supplementation on Kidney Function in Patients With Type 2 Diabetes: A Randomized Clinical Trial.
    de Boer IH; Zelnick LR; Ruzinski J; Friedenberg G; Duszlak J; Bubes VY; Hoofnagle AN; Thadhani R; Glynn RJ; Buring JE; Sesso HD; Manson JE
    JAMA; 2019 Nov; 322(19):1899-1909. PubMed ID: 31703120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, Placebo-Controlled Trial.
    Sircar D; Chatterjee S; Waikhom R; Golay V; Raychaudhury A; Chatterjee S; Pandey R
    Am J Kidney Dis; 2015 Dec; 66(6):945-50. PubMed ID: 26233732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of high-dose atorvastatin on renal function in subjects with stroke or transient ischemic attack in the SPARCL trial.
    Amarenco P; Callahan A; Campese VM; Goldstein LB; Hennerici MG; Messig M; Sillesen H; Welch KM; Wilson DJ; Zivin JA
    Stroke; 2014 Oct; 45(10):2974-82. PubMed ID: 25147328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT).
    Lambers Heerspink HJ; Weldegiorgis M; Inker LA; Gansevoort R; Parving HH; Dwyer JP; Mondal H; Coresh J; Greene T; Levey AS; de Zeeuw D
    Am J Kidney Dis; 2014 Feb; 63(2):244-50. PubMed ID: 24210590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early low-dose erythropoiesis-stimulating agent therapy and progression of moderate chronic kidney disease: a randomized, placebo-controlled trial.
    Fliser D; Dellanna F; Koch M; Wiggenhauser A;
    Nephrol Dial Transplant; 2017 Feb; 32(2):279-287. PubMed ID: 28186540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.
    Yale JF; Bakris G; Cariou B; Nieto J; David-Neto E; Yue D; Wajs E; Figueroa K; Jiang J; Law G; Usiskin K; Meininger G;
    Diabetes Obes Metab; 2014 Oct; 16(10):1016-27. PubMed ID: 24965700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary Potassium Excretion and Renal and Cardiovascular Complications in Patients with Type 2 Diabetes and Normal Renal Function.
    Araki S; Haneda M; Koya D; Kondo K; Tanaka S; Arima H; Kume S; Nakazawa J; Chin-Kanasaki M; Ugi S; Kawai H; Araki H; Uzu T; Maegawa H
    Clin J Am Soc Nephrol; 2015 Dec; 10(12):2152-8. PubMed ID: 26563378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GFR decline and subsequent risk of established kidney outcomes: a meta-analysis of 37 randomized controlled trials.
    Lambers Heerspink HJ; Tighiouart H; Sang Y; Ballew S; Mondal H; Matsushita K; Coresh J; Levey AS; Inker LA
    Am J Kidney Dis; 2014 Dec; 64(6):860-6. PubMed ID: 25441439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of a fixed-dose combination of naproxen and esomeprazole magnesium on serum thromboxane B2 inhibition by low-dose aspirin over 5 days in healthy adults: a phase I, randomized, double-blind, placebo-controlled, noninferiority trial.
    Angiolillo DJ; Hwang C; Datto C; Desai B; Sostek M
    Clin Ther; 2011 Dec; 33(12):1883-93. PubMed ID: 22078153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
    Tanaka A; Shimabukuro M; Okada Y; Taguchi I; Yamaoka-Tojo M; Tomiyama H; Teragawa H; Sugiyama S; Yoshida H; Sato Y; Kawaguchi A; Ikehara Y; Machii N; Maruhashi T; Shima KR; Takamura T; Matsuzawa Y; Kimura K; Sakuma M; Oyama JI; Inoue T; Higashi Y; Ueda S; Node K;
    Cardiovasc Diabetol; 2017 Apr; 16(1):48. PubMed ID: 28403850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility and validity of estimated GFR-based surrogate time-to-event end points in CKD: a simulation study.
    Greene T; Teng CC; Inker LA; Redd A; Ying J; Woodward M; Coresh J; Levey AS
    Am J Kidney Dis; 2014 Dec; 64(6):867-79. PubMed ID: 25441440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial.
    Lambers Heerspink HJ; Chertow GM; Akizawa T; Audhya P; Bakris GL; Goldsberry A; Krauth M; Linde P; McMurray JJ; Meyer CJ; Parving HH; Remuzzi G; Christ-Schmidt H; Toto RD; Vaziri ND; Wanner C; Wittes J; Wrolstad D; de Zeeuw D
    Nephrol Dial Transplant; 2013 Nov; 28(11):2841-50. PubMed ID: 24169612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gain in adiposity over 3 years is associated with progressive renal decline in multi-ethnic South-east Asians with type 2 diabetes.
    Moh MC; Sum CF; Tavintharan S; Ang K; Kwan PY; Lee SBM; Tang WE; Lim SC
    J Diabetes; 2019 Apr; 11(4):316-325. PubMed ID: 30178527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Empagliflozin and Rapid Kidney Function Decline Incidence in Type 2 Diabetes: An Exploratory Analysis From the EMPA-REG OUTCOME Trial.
    Hadjadj S; Cooper ME; Steubl D; Petrini M; Hantel S; Mattheus M; Wanner C; Thomas MC
    Kidney Med; 2024 Mar; 6(3):100783. PubMed ID: 38419787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of thromboxane biosynthesis by triflusal in type 2 diabetes mellitus.
    Falco A; Salvati F; Vitacolonna E; Avellone G; Pinto A; Di Febbo C; Ballone E; Di Nicola M; Ciabattoni G; Davì G
    Atherosclerosis; 2005 Dec; 183(2):329-35. PubMed ID: 16285996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON).
    de Zeeuw D; Akizawa T; Agarwal R; Audhya P; Bakris GL; Chin M; Krauth M; Lambers Heerspink HJ; Meyer CJ; McMurray JJ; Parving HH; Pergola PE; Remuzzi G; Toto RD; Vaziri ND; Wanner C; Warnock DG; Wittes J; Chertow GM
    Am J Nephrol; 2013; 37(3):212-22. PubMed ID: 23467003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.